tradmap

COCH Earnings Envoy Medical, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$25 -$13 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $158000 $316000 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$30M -$15M $0 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$4 -$1 $1 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $47500 $95000 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$7M -$3M $2M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–19 of 19
Q2 20262026-06-30-0.702026-08-1010-Q
Q1 20262026-03-31-0.802026-05-1110-Q
Q4 2025 (derived)2025-12-31-2.702026-03-2310-K
FY 20252025-12-31-12.302026-03-2310-K
Q3 20252025-09-30-3.502025-11-1010-Q
Q2 20252025-06-30-3.202025-07-3110-Q
Q1 20252025-03-31-2.902025-05-0110-Q
Q4 2024 (derived)2024-12-31-4.002025-03-3110-K
FY 20242024-12-31-14.902025-03-3110-K
Q3 20242024-09-30-3.902024-11-1410-Q
Q2 20242024-06-30-2.902024-08-1210-Q
Q1 20242024-03-31-4.102024-05-1510-Q
Q4 2023 (derived)2023-12-31-0.502024-04-0110-K
FY 20232023-12-31-25.402024-04-0110-K
Q3 20232023-09-301.302023-11-1710-Q
Q2 20232023-06-30-13.10——
Q1 20232023-03-31-13.10——
FY 20222022-12-31-15.70——
Q3 20222022-09-30-1.30——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.